Sanofi to Buy Rare-Disease Assets From Inhibrx
Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.
ADM Puts CFO on Leave as Farm Giant Probes Accounting Read More »
A Lamborghini-Style EV: BYD Goes Upmarket to Outmaneuver Tesla Read More »
Tired of Chicken Yet? The Restaurant Industry Bets the Answer Is No Read More »
Boeing Snafus Add New Risks to 2024 Production Goals Read More »